bullish

Maze Therapeutics Inc. (MAZE): Phase 2 Biopharma Targeting Kidney Disease Files for IPO.

459 Views17 Jan 2025 15:02
​A biotech company is developing precision medicine-based treatments for chronic kidney disease, with Phase 2 trials underway and plans for a debut in late January/early February.
What is covered in the Full Insight:
  • Company Overview
  • Lead Program: MZE829
  • Secondary Drug: MZE782
  • Potential IPO Timing
  • Existing Shareholders
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Related Insights
More »
    Loading
Trending Collections
More »
    Loading
Trending Insights
More »
    Loading
Top Unpaywalled Insights
More »
    Loading
Discussions
(Paid Plans Only)
chart-bar
x